Mirada Medical Announces The Release Of Its Advanced XD3 PET-CT And Fusion Package On Sectra PACS

Mirada Medical Limited, the fast growing international company focused on advanced oncology imaging, announced recently that its latest XD3 multi-modality image fusion analysis package is now available as an option to users of Sectra PACS.

The latest version of Mirada XD3 is now available fully integrated into the Sectra workflow. This delivers greatly improved levels of productivity to radiologists and other users of medical imaging who want to access the most advanced tools and products from one workstation and without having to copy large quantities of image data from one location to another.

Using XD3,Sectra users can now be offered advanced quantification of PET, CT, MRI and SPECT including SUV measurements and access to standard disease response protocols such as RECIST for CT and PERCIST for PET and PETCT. The Mirada software supports comparison of two or more PET/CTs and also allows users to fuse MRI with PET, SPECT or CT. Mirada's XD3 application also incorporates the latest versions of Mirada's leading deformable image registration algorithms, which allow any combination of image modalities to be registered non-rigidly allowing for corrections to be made where patient positioning is inconsistent, or patient anatomy has changed over time.

Commenting on the new product release, Hugh Bettesworth, CEO of Mirada Medical, said: "It is central to Mirada's philosophy that we make the advanced technologies available to the widest range of clinical users. By tightly integrating our XD3 application on Sectra PACS, users of this system can experience what we believe are the leading multi-modality workflows in the world, and do so in a way that can significantly boost productivity allowing more scans to be accurately analysed and reported."

Commenting for Sectra, Per Elmhester, Product Manager Clinical Solutions said: "Sectra strives to constantly improve the offering to our customers. With this release our customers can now fully enjoy the benefits of the Mirada XD3-package."

About Mirada Medical
Mirada Medical Limited develops internationally recognised medical imaging analysis applications that provide clinicians with advanced software applications for the quantification of images which are typically used in cancer diagnosis and treatment response assessment. Mirada Medical's technology has broad applicability across nuclear medicine, diagnostic radiology, radiation oncology and medical oncology. Mirada Medical also markets products in neurology and cardiology. Mirada specialises in offering comprehensive and quantifiable analysis for the diagnosis, staging, treatment planning and assessment of treatment response in oncology. Mirada's advanced technology allows medical images acquired using MRI, CT, SPECT or PET scanners to be combined into one, a process known as image fusion. Image fusion is useful in clinical interpretation as it allows different qualities of information to be combined into a single picture, for example, functional information such as metabolic activity, to be combined with anatomical information showing the precise location of pathology relative to bones and organs. This provides clinical users with a more complete picture, thereby improving the quality of information available when managing a patient's condition. Mirada's products are designed to support the comparison of multi-modal images acquired over any number of follow up visits by the patient, making them particularly well suited to the analysis of treatment response in longer term treatment plans such as those typical when treating cancer.

Mirada Medical was formed out of Oxford University by Professor Sir Michael Brady, one of the world's leading medical imaging scientists. The Company is ISO 13485 certified and its technology has been supplied globally to customers in countries including the US, Japan, and Europe since 2001. Mirada's products are sold by Mirada but also by major healthcare players such as McKesson, Siemens, Sectra, Carestream and Vital Images.

The Mirada team is a combination of world class scientists and exceptional engineers sourced from both Oxford University and leading blue-chip companies. For more information, visit www.mirada-medical.com.

About XD3
Mirada's XD3 multi-modality clinical reading application empowers radiologists and oncologists with the image analysis they need to diagnose disease and assess follow up to treatment. XD3 combines powerful registration technologies with serial review of acquisitions acquired over time. Key product features include disease specific oncology workflows and fast, accurate and reproducible image quantification, Mirada's world class image registration engine powers multi-modal fusion and registration across time. XD3 facilitates advanced clinical decision support and may be deployed on PACS, workstation or laptop, providing the most flexible workflow integration available anywhere. Mirada Medical continues to develop superior products to suit the needs of clinicians for reviewing images in diagnosing, staging and evaluating disease progression and response to therapy. Mirada's XD3 product provides comprehensive levels of analytical power to the clinical user. Featuring powerful disease specific oncology workflows and fast, accurate and reproducible image quantification, XD3 facilitates advanced clinical decision support. XD3 may be deployed on PACS, home workstation or laptop, providing the most productive workflow integration available anywhere.

About the Sectra Group
Sectra successfully develops and sells cutting-edge products in the expansive niche segments of medical systems and secure communication systems. The company was founded in 1978 and has its roots in Linköping University in Sweden. Today, Sectra has offices in twelve countries and operates through partners worldwide. Sales in the 2009/2010 fiscal year totaled SEK 848 million. The Sectra share is quoted on the NASDAQ OMX Stockholm AB exchange. For more information, visit www.sectra.com.

About Sectra's medical operations
Sectra develops and sells IT-systems and products for radiology, mammography and orthopedics. More than 1,100 hospitals, clinics and imaging centers worldwide use the systems daily, together performing over 52 million radiology examinations annually. This makes Sectra one of the world-leading companies within systems for handling digital radiology images. In Scandinavia, Sectra is the market leader with more than 50% of all filmfree installations. Sectra's systems have been installed in North America, Scandinavia and most major countries in Europe and the Far East.

SOURCE: Mirada Medical Limited